Korean biosimilar company Samsung Bioepis is presenting new data on its copy of Humira (adalimumab), which is branded as Imraldi and Hadlima and also referred t 1 June 2022
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
USA-based Insmed (NASDAQ CM: INSM) is a biopharmaceutical company on the development and commercialization of novel, targeted inhaled therapies for patients with serious rare diseases.